Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center Experience.

Yang, OCY; Chiang, Y-H; Chen, CG; Chang, Y-C; Chang, M-C; Lin, H-C; Lin, J; Lim, K-H

Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center Experience.

Yang, OCY Chiang, Y-H Chen, CG Chang, Y-C Chang, M-C Lin, H-C Lin, J Lim, K-H

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Cancer Rep (Hoboken), 2025, 8, (12), pp. e70367
Issue Date:: 2025-12

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (512.72 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Yang, OCY
dc.contributor.author	Chiang, Y-H
dc.contributor.author	Chen, CG
dc.contributor.author	Chang, Y-C
dc.contributor.author	Chang, M-C
dc.contributor.author	Lin, H-C
dc.contributor.author	Lin, J
dc.contributor.author	Lim, K-H
dc.date.accessioned	2026-07-02T03:21:22Z
dc.date.available	2025-10-06
dc.date.available	2026-07-02T03:21:22Z
dc.date.issued	2025-12
dc.identifier.citation	Cancer Rep (Hoboken), 2025, 8, (12), pp. e70367
dc.identifier.issn	2573-8348
dc.identifier.issn	2573-8348
dc.identifier.uri	http://hdl.handle.net/10453/195527
dc.description.abstract	BACKGROUND: Daratumumab represents the first-in-class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM). Evidence from randomized controlled trials has shown daratumumab to be efficacious in the setting of second-line combinational therapy for pretreated multiple myeloma. However, real-world evidence that supports daratumumab use in daily clinical practice remains scarce. AIM: The primary objective of this study was to describe the real-world clinical and adverse effects observed in RRMM patients receiving daratumumab as second-line therapy. METHODS: This was an observational case series with a retrospective chart review of pretreated multiple myeloma patients who received daratumumab-based combinational therapy at an academic medical center. The primary end point was progression-free survival. Additional end points included overall response rates, adverse effects of daratumumab therapy, and subsequent treatment options following daratumumab. RESULTS: Seventeen patients were included. The overall response rate of daratumumab in our patients with RRMM was 13/17 (76.5%), and the median progression-free survival was 20 months when daratumumab was used in the second-line setting. Common adverse effects included neutropenia (52.9%), thrombocytopenia (64.7%), anemia (35.7%), and pneumonia (35.3%). On follow-up, 10 patients remained alive at the experimental cut-off date, with 2 patients kept on daratumumab-based combinational therapy; 5 patients were switched to carfilzomib-based therapy; and 3 received best supportive care. CONCLUSION: In our single-center experience with Taiwanese RRMM patients, daratumumab in combinational therapy showed promising efficacy, and modest tolerance in the second-line setting.
dc.format	Print
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Cancer Rep (Hoboken)
dc.relation.isbasedon	10.1002/cnr2.70367
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	3211 Oncology and carcinogenesis
dc.subject.mesh	Humans
dc.subject.mesh	Multiple Myeloma
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Aged
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Middle Aged
dc.subject.mesh	Antibodies, Monoclonal
dc.subject.mesh	Neoplasm Recurrence, Local
dc.subject.mesh	Progression-Free Survival
dc.subject.mesh	Drug Resistance, Neoplasm
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Adult
dc.subject.mesh	Oligopeptides
dc.subject.mesh	Humans
dc.subject.mesh	Multiple Myeloma
dc.subject.mesh	Neoplasm Recurrence, Local
dc.subject.mesh	Oligopeptides
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Antibodies, Monoclonal
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Drug Resistance, Neoplasm
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Progression-Free Survival
dc.subject.mesh	Humans
dc.subject.mesh	Multiple Myeloma
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Aged
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Middle Aged
dc.subject.mesh	Antibodies, Monoclonal
dc.subject.mesh	Neoplasm Recurrence, Local
dc.subject.mesh	Progression-Free Survival
dc.subject.mesh	Drug Resistance, Neoplasm
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Adult
dc.subject.mesh	Oligopeptides
dc.title	Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center Experience.
dc.type	Journal Article
utslib.citation.volume	8
utslib.location.activity	United States
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Computer Science
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Artificial Intelligence Institute (AAII)
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2026-07-02T03:21:20Z
pubs.issue	12
pubs.publication-status	Published
pubs.volume	8
utslib.citation.issue	12

Abstract:

BACKGROUND: Daratumumab represents the first-in-class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM). Evidence from randomized controlled trials has shown daratumumab to be efficacious in the setting of second-line combinational therapy for pretreated multiple myeloma. However, real-world evidence that supports daratumumab use in daily clinical practice remains scarce. AIM: The primary objective of this study was to describe the real-world clinical and adverse effects observed in RRMM patients receiving daratumumab as second-line therapy. METHODS: This was an observational case series with a retrospective chart review of pretreated multiple myeloma patients who received daratumumab-based combinational therapy at an academic medical center. The primary end point was progression-free survival. Additional end points included overall response rates, adverse effects of daratumumab therapy, and subsequent treatment options following daratumumab. RESULTS: Seventeen patients were included. The overall response rate of daratumumab in our patients with RRMM was 13/17 (76.5%), and the median progression-free survival was 20 months when daratumumab was used in the second-line setting. Common adverse effects included neutropenia (52.9%), thrombocytopenia (64.7%), anemia (35.7%), and pneumonia (35.3%). On follow-up, 10 patients remained alive at the experimental cut-off date, with 2 patients kept on daratumumab-based combinational therapy; 5 patients were switched to carfilzomib-based therapy; and 3 received best supportive care. CONCLUSION: In our single-center experience with Taiwanese RRMM patients, daratumumab in combinational therapy showed promising efficacy, and modest tolerance in the second-line setting.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/195527